Compare Domino's Pizza, Inc. (DPZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Domino's Pizza, Inc. trades at $309.23 (market cap $10.21B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Domino's Pizza, Inc. is far larger — about 4.8× Recursion Pharmaceuticals Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DPZ | RXRX | |
|---|---|---|
Market Cap | $10.21B | $2.14B |
Volume | 916,737 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $6.79 |
52-Week Low | $282.89 | $2.84 |
Typical Hold Time | 106 Days | 23 Days |
Enterprise Value | $15.17B | $1.66B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $309.36, up 2.07% today, amid a mixed technical and fundamental backdrop. The stock shows a bullish overall technical signal but has missed earnings estimates for three consecutive quarters. Revenue and net income have grown steadily, reaching $4.94 billion and $601.70 million in 2025, respectively, though profit margins are under slight pressure. Recent news highlights store closures and dividend stability concerns alongside promotional initiatives.
The outlook is cautiously optimistic, supported by analyst consensus but tempered by high debt and recent earnings misses. Investment opportunity lies in potential valuation expansion toward the $373 price target, while key risks include elevated leverage, competitive pressures, and execution challenges in maintaining growth.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
